Neohepatect (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin contains purified polyclonal anti‑HBs antibodies. After intravenous infusion, these antibodies bind to hepatitis B surface antigens on circulating virus particles, neutralising them and blocking attachment to hepatocyte receptors. This prevents viral entry into liver cells, offering short‑term protection while the patient’s own immune system or antiviral therapy takes effect.

The dose of Neohepatect is determined by the prescribing clinician based on the indication, patient weight, and exposure risk. Healthcare professionals calculate the appropriate volume of the sterile solution to achieve the required anti‑HBs antibody titre. Exact dosing regimens are not disclosed publicly and should follow the prescriber’s order and local guidelines.

Safety data for Neohepatect in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Clinicians must weigh the potential benefits of preventing hepatitis B infection against any theoretical risks to the fetus or infant. Use is generally reserved for situations where the benefit justifies potential exposure, and decisions should be made by the treating physician.

To order Neohepatect, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Neohepatect provides passive immunity through anti‑HBs antibodies, offering immediate protection, whereas hepatitis B vaccines stimulate active immunity over weeks. Compared with antiviral agents, Neohepatect does not suppress viral replication but prevents initial infection. In settings such as liver transplantation or acute exposure, passive immunoglobulin is preferred for rapid protection, while vaccines are used for long‑term immunity.

Neohepatect should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Maintaining the cold chain is essential to preserve antibody integrity and ensure efficacy at the time of administration.

Neohepatect is administered intravenously by a qualified healthcare professional. The sterile solution is infused over a period determined by the prescriber, typically ranging from a few minutes to an hour, depending on the patient’s condition and tolerance. Monitoring for infusion‑related reactions during and after the administration is recommended.

The most serious risks associated with Neohepatect include anaphylactic reactions, serum sickness, and severe hypotension. These events are rare but require immediate medical attention. Patients should be observed closely during infusion, and any signs of allergic response—such as rash, difficulty breathing, or sudden drop in blood pressure—should prompt emergency intervention.

Neohepatect is contraindicated in individuals with a known hypersensitivity to human immunoglobulin products or any component of the formulation. Patients with a history of severe allergic reactions to blood‑derived products should avoid its use. Additionally, it should not be given concurrently with live viral vaccines, as it may diminish vaccine efficacy.